Johnson & Johnson stock (NYSE: JNJ) received two critical approvals this year from the US Food and Drug Administration (FDA).The approvals received were for the medicines Icotyde and Rybrevant. While Icotyde is a daily oral pill for Psoriasis, Rybrevant will be used for lung cancer therapy. Rybrevant was approved by the FDA in February, and Icotyde’s approval came in March 2026, receiving regulatory green light to sell.

The approvals made Johnson & Johnson’s stock surge in value this year due to the key breakthrough in medicine. JNJ has climbed nearly 11.5% year-to-date, going from a low of $207 to a high of $248 in March. It opened Tuesday’s bell at $230 and is on course to reclaim its yearly high.

However, 2 other FDA approvals are in line that can make or break Johnson & Johnson’s stock price. The pharmaceutical company has submitted one for review with the FDA, and the other still remains in the testing phase. In this article, we will explain the upcoming approvals and how they will help JNJ stock surge in value.

Also Read:Tim Cook Resigns & Will Step Down on Sep 1: What Next For Apple Stock?

The 2 drugs in process for an FDA nod from Johnson & Johnson are:

Ottavais a robotic surgery system and is currently under FDA review, needing regulatory clearance. This is the major catalyst, as it involves the MedTech system. The pharma giant submitted the trials and documents in January 2026 to the department. Investors are waiting for the FDA’s decision, and a ‘yes’ would give Johnson & Johnson stock the much-needed boost in the charts.

JNJ-78934804is a combination therapy for gut health and is currently in clinical trials. The testing and research phase is ongoing, and it is reported that the company might submit it to the FDA in 2027. If this receives the nod, Johnson & Johnson stock could be set for the long term in 2027 and beyond. While Ottava’s approval can set JNJ in motion in 2026, JNJ-78934804’s approval can continue the momentum in 2027. This fills the gap on both short-term and long-term profits from the pharma giant.

Source: Watcher Guru